Trupanion earnings release, August 5, 2026

Trupanion, Inc. (TRUP) · Form 8-K, Item 2.02 · Filed · SEC filing

Trupanion Reports Second Quarter 2026 Results

Authorizes Share Repurchase Program

SEATTLE, WA. August 5, 2026 --

Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, today announced financial results for the second quarter ended June 30, 2026.

“We continue to execute on the priorities that matter most by growing margin, improving the economics of new enrollments, and investing our capital with discipline,” said Margi Tooth, Chief Executive Officer and President of Trupanion. “As our business continues to compound, we have more opportunities to allocate capital where we believe it will create lasting shareholder value.”

Second Quarter 2026 Financial and Business Highlights

• Total revenue was $392.9 million, an increase of 11% compared to the second quarter of 2025.

• Total enrolled pets (including pets from our other business segment) was 1,633,131 at June 30, 2026, a decrease of 2% over June 30, 2025.

• Subscription business revenue was $276.7 million, an increase of 14% compared to the second quarter of 2025.

• Subscription enrolled pets was 1,124,548 at June 30, 2026, an increase of 5% over June 30, 2025.

• Net income was $6.8 million, or $0.16 per basic and diluted share, compared to net income of $9.4 million, or $0.22 per basic and diluted share, in the second quarter of 2025.

• Adjusted EBITDA was $19.8 million, compared to adjusted EBITDA of $16.6 million in the second quarter of 2025.

• Operating cash flow was $21.0 million and free cash flow was $19.2 million in the second quarter of 2026. This compared to operating cash flow of $15.0 million and free cash flow of $12.0 million in the second quarter of 2025.

First Six Months 2026 Financial and Business Highlights

• Total revenue was $777.0 million, an increase of 12% compared to the first six months of 2025.

• Subscription business revenue was $546.1 million, an increase of 15% compared to the first six months of 2025.

• Net income was $11.7 million, or $0.27 per basic and diluted share, compared to net income of $7.9 million, or $0.19 per basic and $0.18 per diluted share, in the first six months of 2025.

• Adjusted EBITDA was $37.1 million, compared to adjusted EBITDA of $28.8 million in the first six months of 2025.

• Operating cash flow was $35.6 million and free cash flow was $32.9 million in the first six months of 2026. This compared to operating cash flow of $31.0 million and free cash flow of $26.1 million in the first six months of 2025.

• At June 30, 2026, the Company held $398.5 million in cash and short-term investments with an additional $3.5 million available under its credit facility.

Extraordinary Dividend and Share Repurchase Authorization

In July 2026, the New York Department of Financial Services approved an extraordinary dividend of $44 million to be paid to Trupanion by its wholly-owned subsidiary, American Pet Insurance Company.

The Board has authorized a share repurchase program, pursuant to which the Company may repurchase up to an aggregate of $100.0 million of its outstanding shares of common stock, with no expiration date. The Company is not obligated to repurchase any specific number or dollar amount of shares, and the timing and actual number of shares repurchased will depend on a variety of factors, including the Company’s compliance with the PNC credit facility, available cash, cash flow from operations, stock price, general economic, business and market conditions, and alternative investment opportunities.¹

Conference Call

Trupanion’s management will host a conference call today to review its second quarter 2026 results. The call is scheduled to begin shortly after 1:30 p.m. PT/ 4:30 p.m. ET. A live webcast will be accessible through the Investor Relations section of Trupanion’s website at https://investors.trupanion.com/ and will be archived online for 3 months upon completion of the conference call. Participants can access the conference call by dialing 1-844-676-1342 (United States) or 1-412-634-6683 (International). A telephonic replay of the call will also be available after the completion of the call, by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) and entering the replay pin number: 10210053.

About Trupanion

Trupanion is a leader in medical insurance for cats and dogs throughout the United States, Canada, and certain countries in Continental Europe with over 1,100,000 pets currently enrolled. For 26 years, Trupanion has given pet owners peace of mind so they can focus on their pet's recovery, not financial stress. Trupanion is committed to providing pet parents with the highest value in pet medical insurance with unlimited payouts on eligible expenses for the life of their pets. With its patented process, Trupanion is the only North American provider with the technology to pay veterinarians directly in seconds at the time of checkout. Trupanion is listed on NASDAQ under the symbol "TRUP". The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company or ZPIC Insurance Company and, in Canada, by its wholly-owned insurance entity GPIC Insurance Company or by Accelerant Insurance Company of Canada. For more information, please visit trupanion.com.

Financial statements

Income Statement (in thousands, except share data)

Three Months Ended June 30, – 2026 – (unaudited)2026Three Months Ended June 30, – 2026Six Months Ended June 30, – 2026 – (unaudited)2026Six Months Ended June 30, – 2026
Revenue:Subscription business276,690546,144
Revenue:Other business116,244230,839
Revenue:Total revenue392,934776,983
Cost of revenue:Subscription business220,254436,706
Cost of revenue:Other business107,547213,655
Cost of revenue:Total cost of revenue(1), (2)327,801650,361
Operating expenses:Technology and development(1)12,75424,048
Operating expenses:General and administrative(1)19,52538,627
Operating expenses:New pet acquisition expense(1)22,80545,416
Operating expenses:Depreciation and amortization3,6737,379
Operating expenses:Total operating expenses58,757115,470
Operating expenses:Operating income6,37611,152
Operating expenses:Interest expense1,8323,707
Operating expenses:Other (income), net-2,829-5,884
Operating expenses:Income before income taxes7,37313,329
Operating expenses:Income tax expense5421,618
Operating expenses:Net income6,83111,711
Net income per share:Basic0.160.27
Net income per share:Diluted0.160.27
Weighted average shares of common stock outstanding:Basic43,730,57343,618,710
Weighted average shares of common stock outstanding:Diluted43,821,06143,751,785
Weighted average shares of common stock outstanding:(1)Includes stock-based compensation expense as follows:Three Months Ended June 30,Six Months Ended June 30,
Weighted average shares of common stock outstanding:(1)Includes stock-based compensation expense as follows:Three Months Ended June 30,Six Months Ended June 30,
Weighted average shares of common stock outstanding:Veterinary invoice expense5051,065
Weighted average shares of common stock outstanding:Other cost of revenue6201,189
Weighted average shares of common stock outstanding:Technology and development2,8654,372
Weighted average shares of common stock outstanding:General and administrative4,7389,631
Weighted average shares of common stock outstanding:New pet acquisition expense1,2412,712
Weighted average shares of common stock outstanding:Total stock-based compensation expense9,96918,969
(2)The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows:Veterinary invoice expense279,468560,904
(2)The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows:Other cost of revenue48,33389,457
(2)The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows:Total cost of revenue327,801650,361

Income Statement (in thousands except percentages)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Veterinary invoice expense279,468255,580560,904503,030
Less:Stock-based compensation expense(1)-496-758-1,048-1,522
Less:Other business cost of paying veterinary invoices(2)-84,665-82,706-174,687-161,975
Less:Subscription cost of paying veterinary invoices (non-GAAP)194,307172,116385,169339,533
Less:% of subscription revenue70.271.170.571.4
Less:Other cost of revenue48,33343,15089,45786,572
Less:Stock-based compensation expense(1)-615-601-1,178-1,082
Less:Other business variable expenses(2)-22,881-20,531-38,964-42,267
Less:Subscription variable expenses (non-GAAP)24,83722,01849,31543,223
Less:% of subscription revenue99.199.1
Less:Technology and development expense12,7548,58624,04816,658
Less:General and administrative expense19,52520,12238,62740,014
Less:Stock-based compensation expense(1)-7,545-6,393-13,820-11,788
Less:Development expenses(3)-1,801-946-3,501-2,353
Less:Fixed expenses (non-GAAP)22,93321,36945,35442,531
Less:% of total revenue5.865.86.1
Less:New pet acquisition expense22,80519,84345,41640,359
Less:Stock-based compensation expense(1)-1,227-1,516-2,652-4,390
Less:Other business pet acquisition expense(2)-15-74-41-77
Less:Subscription acquisition cost (non-GAAP)21,56318,25342,72335,892
Less:% of subscription revenue7.87.57.87.6

Income Statement (in thousands, except percentages)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating income6,3762,31411,152841
Non-GAAP expense adjustmentsAcquisition cost21,57818,32742,76435,969
Non-GAAP expense adjustmentsStock-based compensation expense(1)9,8839,26818,69818,782
Non-GAAP expense adjustmentsDevelopment expenses(2)1,8019463,5012,353
Non-GAAP expense adjustmentsDepreciation and amortization3,6733,9627,3797,753
Non-GAAP expense adjustmentsLoss from investment in joint venture-305
Non-GAAP expense adjustmentsTotal adjusted operating income (non-GAAP)43,31134,81783,49466,003
Subscription Business:Subscription operating income8,3314,52314,8245,590

Income Statement (in thousands, except percentages)

Three Months Ended June 30, – 20262026Three Months Ended June 30, – 20262025Three Months Ended June 30, – 2025Six Months Ended June 30, – 20262026Six Months Ended June 30, – 20262025Six Months Ended June 30, – 2025
Subscription revenue276,690242,156546,144475,220
Subscription cost of paying veterinary invoices194,307172,116385,169339,533
Subscription variable expenses24,83722,01849,31543,223
Subscription fixed expenses*16,14914,63631,87929,058
Subscription adjusted operating income (non-GAAP)41,39733,38679,78163,406
Other business revenue116,244111,401230,839220,312
Other business cost of paying veterinary invoices84,66582,706174,687161,975
Other business variable expenses22,88120,53138,96442,267
Other business fixed expenses*6,7846,73313,47513,473
Other business adjusted operating income (non-GAAP)1,9141,4313,7132,597
Revenue392,934353,557776,983695,532
Cost of paying veterinary invoices278,972254,822559,856501,508
Variable expenses47,71842,54988,27985,490
Fixed expenses*22,93321,36945,35442,531
Total business adjusted operating income (non-GAAP)43,31134,81783,49466,003
As a percentage of revenue:Three Months Ended June 30,Six Months Ended June 30,
Subscription revenue100100100100
Subscription cost of paying veterinary invoices70.271.170.571.4
Subscription variable expenses99.199.1
Subscription fixed expenses*5.865.86.1
Subscription adjusted operating income (non-GAAP)1513.814.613.3
Other business revenue100100100100
Other business cost of paying veterinary invoices72.874.275.773.5
Other business variable expenses19.718.416.919.2
Other business fixed expenses*5.865.86.1
Other business adjusted operating income (non-GAAP)1.61.31.61.2
Revenue100100100100
Cost of paying veterinary invoices7172.172.172.1
Variable expenses12.11211.412.3

Income Statement (in thousands)

Three Months Ended – Jun. 30, 2026Six Months Ended June 30, – 2026Three Months Ended – Jun. 30, 2026Six Months Ended June 30, – 2025Three Months Ended – Mar. 31, 2026Three Months Ended – Dec. 31, 2025Three Months Ended – Sep. 30, 2025Three Months Ended – Jun. 30, 2025Three Months Ended – Mar. 31, 2025Three Months Ended – Dec. 31, 2024Three Months Ended – Sep. 30, 2024
Net income11,7117,930
Excluding:Stock-based compensation expense(1)18,69818,782
Excluding:Depreciation and amortization expense7,3797,753
Excluding:Interest income-5,981-5,940
Excluding:Interest expense3,7076,893
Excluding:Income tax expense1,6181,172
Excluding:Realized gain on nonmonetary exchange of preferred stock investment-7,783
Excluding:Adjusted EBITDA37,13228,807
Excluding:Net income (loss)6,8314,8805,6305,8739,413-1,4831,6561,425
Excluding:Stock-based compensation expense(1)9,8838,8159,3619,3239,2689,5148,0368,127
Excluding:Depreciation and amortization expense3,6733,7064,0324,0513,9623,7913,9244,381
Excluding:Interest income-2,983-2,998-3,115-3,201-3,105-2,835-2,999-3,232
Excluding:Interest expense1,8321,8754,0762,7903,6823,2113,4273,820
Excluding:Income tax expense5421,0766637261,133393839
Excluding:Goodwill impairment charges1,1295,299
Excluding:Loss from equity method investment-33
Excluding:Realized gain on nonmonetary exchange of preferred stock investment-7,783
Excluding:Adjusted EBITDA19,77817,35421,77619,56216,57012,23719,38114,527

Balance Sheet (in thousands, except share data)

June 30, 2026 – (unaudited)December 31, 2025
Current assets:Cash and cash equivalents149,360138,024
Current assets:Short-term investments249,131232,706
Current assets:Accounts and other receivables, net of allowance for credit losses of $2,886 at June 30, 2026 and $1,311 at December 31, 2025302,191301,945
Current assets:Prepaid expenses and other assets18,76018,387
Current assets:Total current assets719,442691,062
Current assets:Restricted cash28,93933,434
Current assets:Long-term investments989983
Current assets:Property, equipment, and internal-use software, net101,425104,844
Current assets:Intangible assets, net23,34424,102
Current assets:Other long-term assets18,04721,237
Current assets:Goodwill38,62539,382
Current assets:Total assets930,811915,044
Current liabilities:Accounts payable11,96516,445
Current liabilities:Accrued liabilities and other current liabilities44,63856,509
Current liabilities:Reserve for veterinary invoices51,72255,921
Current liabilities:Deferred revenue287,156270,935
Current liabilities:Long-term debt - current portion10,00010,000
Current liabilities:Total current liabilities405,481409,810
Current liabilities:Long-term debt96,909101,784
Current liabilities:Deferred tax liabilities6391,510
Current liabilities:Other liabilities18,11218,004
Current liabilities:Total liabilities521,141531,108
Stockholders’ equity:Additional paid-in capital623,566604,828
Stockholders’ equity:Accumulated other comprehensive income (loss)-2,6182,097
Stockholders’ equity:Accumulated deficit-194,744-206,455
Stockholders’ equity:Treasury stock, at cost: 1,028,186 shares at June 30, 2026 and December 31, 2025-16,534-16,534
Stockholders’ equity:Total stockholders’ equity409,670383,936
Stockholders’ equity:Total liabilities and stockholders’ equity930,811915,044

Cash Flow (in thousands)

Three Months Ended June 30, – 2026 – (unaudited)Three Months Ended June 30, – 2025 – (unaudited)Six Months Ended June 30, – 2026 – (unaudited)Six Months Ended June 30, – 2025 – (unaudited)
Net income6,8319,41311,7117,930
Adjustments to reconcile net income to cash provided by operating activities:Depreciation and amortization3,6733,9627,3797,753
Adjustments to reconcile net income to cash provided by operating activities:Stock-based compensation expense9,9699,45618,96919,286
Adjustments to reconcile net income to cash provided by operating activities:Realized gain on nonmonetary exchange of preferred stock investment-7,783-7,783
Adjustments to reconcile net income to cash provided by operating activities:Other, net-164601-378951
Changes in operating assets and liabilities:Accounts and other receivables2,408-2,050-627-18,015
Changes in operating assets and liabilities:Prepaid expenses and other assets643-3802,597-584
Changes in operating assets and liabilities:Accounts payable, accrued liabilities, and other liabilities1,529-536-16,797990
Changes in operating assets and liabilities:Reserve for veterinary invoices-4,891-1,710-4,048697
Changes in operating assets and liabilities:Deferred revenue9864,05116,77219,764
Changes in operating assets and liabilities:Net cash provided by operating activities20,98415,02435,57830,989

Cash Flow (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net cash provided by operating activities20,98415,02435,57830,989
Purchases of property, equipment, and internal-use software-1,825-2,977-2,672-4,904
Free cash flow19,15912,04732,90626,085
Full release

Forward-Looking Statements... (truncated)release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements made in this press release are based on information available to Trupanion as of the date hereof, and Trupanion has no obligation to update these forward-looking statements.

In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the ability to achieve or maintain profitability and/or appropriate levels of cash flow in future periods; the ability to keep growing our membership base and revenue; the accuracy of assumptions used in determining appropriate member acquisition expenditures; the severity and frequency of claims; the ability to maintain high retention rates; the accuracy of assumptions used in pricing medical plan subscriptions and the ability to accurately estimate the impact of new products or offerings on claims frequency; actual claims expense exceeding estimates; regulatory and other constraints on the ability to institute, or the decision to otherwise delay, pricing modifications in response to changes in actual or estimated claims expense; the effectiveness and statutory or regulatory compliance of our Territory Partner model and of our Territory Partners, veterinarians and other third parties in recommending medical plan subscriptions to potential members; the ability to retain existing Territory Partners and increase the number of Territory Partners and active hospitals; compliance by us and those referring us members with laws and regulations that apply to our business, including the sale of a pet medical plan; the ability to maintain the security of our data; fluctuations in currency exchange rates; the ability to protect our proprietary and member information; the ability to maintain our culture and team; the ability to maintain the requisite amount of risk-based capital; our ability to implement and maintain effective controls; the ability to protect and enforce Trupanion’s intellectual property rights; the ability to successfully implement our alliance with Aflac; the ability to continue key contractual relationships with third parties; developments relating to our writing of policies for unaffiliated third parties, including Pets Best; the extent to which we consummate our share repurchase plan and related impacts; third-party claims including litigation and regulatory actions; the ability to recognize benefits from investments in new solutions and enhancements to Trupanion’s technology platform and website; our ability to retain key personnel; and deliberations and determinations by the Trupanion board based on the future performance of the company or otherwise.²

For a detailed discussion of these and other cautionary statements, please refer to the risk factors discussed in filings with the Securities and Exchange Commission (SEC), including but not limited to, Trupanion’s Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequently filed reports on Forms 10-Q, 10-K and 8-K. All documents are available through the SEC’s Electronic Data Gathering Analysis and Retrieval system at https://www.sec.gov or the Investor Relations section of Trupanion’s website at https://investors.trupanion.com.

Non-GAAP Financial Measures

Trupanion’s stated results include certain non-GAAP financial measures. These non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in its industry as other companies in its industry may calculate or use non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on Trupanion’s reported financial results. The presentation and utilization of non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Trupanion urges its investors to review the reconciliation of its non-GAAP financial measures to the most directly comparable GAAP financial measures in its consolidated financial statements, and not to rely on any single financial or operating measure to evaluate its business. These reconciliations are included below and on

Trupanion’s Investor Relations website.

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expenses, Trupanion believes that providing various non-GAAP financial measures that exclude stock-based compensation expense and depreciation and amortization expense allows for more meaningful comparisons between its operating results from period to period. Trupanion offsets new pet acquisition expense with sign-up fee revenue in the calculation of net acquisition cost because it collects sign-up fee revenue from new members at the time of enrollment and considers it to be an offset to a portion of Trupanion’s new pet acquisition expense. Trupanion believes this allows it to calculate and present financial measures in a consistent manner across periods. Trupanion’s management believes that the non-GAAP financial measures and the related financial measures derived from them are important tools for financial and operational decision-making and for evaluating operating results over different periods of time.³⁴⁵⁶⁷⁸⁹¹⁰... (truncated). Non-cash items, such as goodwill impairment charges, stock-based compensation expense and depreciation and amortization, are also excluded. Acquisition cost, development expenses, gain (loss) from investment in joint venture, stock-based compensation expense, and depreciation and amortization are expected to remain recurring expenses for the foreseeable future, but are excluded from this metric to measure scale in other areas of the business. Management believes acquisition costs primarily represent the cost to acquire new subscribers and are driven by the amount of growth we choose to pursue based primarily on the amount of our adjusted operating income period over period. Accordingly, this measure is not indicative of our core operating income performance. We also exclude development expenses, gain (loss) from investment in joint venture, stock-based compensation expense, and depreciation and amortization because some investors may not view those items as reflective of our core operating income performance.

Management uses adjusted operating income and the margin on adjusted operating income to understand the effects of scale in its non-acquisition cost and development expenses and to plan future advertising expenditures, which are designed to acquire new pets. Management uses this measure as a principal way of understanding the operating performance of its business exclusive of acquisition cost and new product exploration and development initiatives. Management believes disclosure of this metric provides investors with the same data that the Company employs in assessing its overall operations and that disclosure of this measure may provide useful information regarding the efficiency of our utilization of revenues, return on advertising dollars in the form of new subscribers and future use of available cash to support the continued growth of our business.¹¹¹²

Contacts

:

Investors:

Laura Bainbridge, Senior Vice President, Corporate Communications

Gil Melchior, Director, Investor Relations

Investor.Relations@trupanion.com¹³

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Trupanion earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.